Developing Story
Hikma v. Amarin – Pharma Patent Pleading Standard (SCOTUS, 2026)
Hikma v. Amarin is a significant pharmaceutical patent case before the Supreme Court addressing what plaintiffs must plead to establish induced infringement when a generic drug uses a Hatch-Waxman skinny label. The outcome will materially affect generic drug market entry strategy and brand patent enforcement.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Hikma v. Amarin – Pharma Patent Pleading Standard (SCOTUS, 2026)
A pending or recently argued Supreme Court case addressing the pleading standard for induced patent infringement claims under 35 U.S.C. § 271(b) in the context of pharmaceutical skinny-label approvals under the Hatch-Waxman Act.
### Legal Background
- The **Hatch-Waxman Act Section VIII pathway** ("skinny label") allows generic drug manufacturers to obtain FDA approval for unpatented indications only, avoiding reference to patented uses
- **35 U.S.C. § 271(b)** imposes liability on any party who "actively induces" infringement of a patent
- The tension between these two provisions has been a persistent source of litigation in pharmaceutical patent law
### The Case
- **Hikma Pharmaceuticals** sought FDA approval for a generic version of Amarin's drug using a skinny label, excluding the patented cardiovascular indication
- **Amarin** alleged that Hikma's marketing and labeling nonetheless actively induced physicians to prescribe the drug for the patented use
- The central dispute: what must a plaintiff plead — and ultimately prove — to establish active inducement when a generic uses a skinny label? (IPWatchdog, April 28, 2026)
### Significance
- The case could resolve a circuit split or clarify the pleading standard for induced infringement in the skinny-label context
- A ruling favoring Amarin would make it easier for brand manufacturers to challenge skinny-label generics
- A ruling favoring Hikma would strengthen the Section VIII pathway and facilitate generic competition
- Affects billions of dollars in pharmaceutical patent litigation strategy and generic drug market entry timing
### Practitioner Implications
- Patent litigators in pharma must monitor the pleading threshold the Court establishes
- Generic manufacturers structuring skinny-label strategies face uncertainty pending the decision
- Brand companies may revisit litigation strategies for off-label use inducement claims